Tandem Auto-Allo Transplant for Lymphoma
Public ClinicalTrials.gov record NCT01181271. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Sequential Myeloablative Autologous Stem Cell Transplantation Followed by Allogeneic Non-Myeloablative Stem Cell Transplantation for Patients With Poor Risk Lymphomas
Study identification
- NCT ID
- NCT01181271
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Massachusetts General Hospital
- Other
- Enrollment
- 42 participants
Conditions and interventions
Conditions
Interventions
- Busulfan (conditioning for ALLO Transplant) Drug
- Busulfan (conditioning for AUTO transplant) Drug
- Cyclophosphamide (conditioning for AUTO transplant) Drug
- Etoposide (conditioning for AUTO transplant) Drug
- Fludarabine (conditioning for ALLO Transplant) Drug
- Mesna (prior to AUTO transplant) Drug
- Methotrexate Drug
- Neupogen Drug
- Sirolimus Drug
- Tacrolimus Drug
- autologous (auto) peripheral blood stem cell transplantation Other
- non-myeloablative allogeneic (allo) transplant Other
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2010
- Primary completion
- Jan 31, 2014
- Completion
- Jan 31, 2016
- Last update posted
- Mar 8, 2017
2010 – 2016
United States locations
- U.S. sites
- 2
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02115 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01181271, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 8, 2017 · Synced May 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01181271 live on ClinicalTrials.gov.